biostudies-literatureJiang XNational Health Commission projectScience and Technology Department of Henan Provincemedical science and technology project of Henan Province272https://www.ebi.ac.uk/biostudies/studies/S-EPMC11368034biostudies-literatureUnknown15(1)<h4>Background</h4>Mesenchymal stem cells (MSCs) possess powerful immunomodulatory ability. This study aimed to assess the efficacy and safety of human umbilical cord-derived mesenchymal stem cells (UMSCs) in patients with ulcerative colitis (UC) and to explore the potential mechanisms.<h4>Methods</h4>This prospective, self-controlled clinical study was conducted at Henan Provincial People's Hospital. Patients with moderate-to-severe active UC, unresponsive to traditional drugs were continuously enrolled from September 2018 to March 2023. UMSCs were administered intravenously monthly for two months at a cell dosage of 1 × 10⁶ per kg. The primary outcome was a clinical response at 2 months. The levels of cytokines and progerin in the plasma of the patients were analyzed using enzStem cell research & therapyUmbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms.PMC11368034SBGJ202001002CMR-20180615-1001212102310203Ding HLiu MLiang YZhang HHuang HBai YHan SYue HShi YLi XLi YYang ZCai CLi ZJiang XPeng CLuo XZhang BfalseUmbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms.<h4>Background</h4>Mesenchymal stem cells (MSCs) possess powerful immunomodulatory ability. This study aimed to assess the efficacy and safety of human umbilical cord-derived mesenchymal stem cells (UMSCs) in patients with ulcerative colitis (UC) and to explore the potential mechanisms.<h4>Methods</h4>This prospective, self-controlled clinical study was conducted at Henan Provincial People's Hospital. Patients with moderate-to-severe active UC, unresponsive to traditional drugs were continuously enrolled from September 2018 to March 2023. UMSCs were administered intravenously monthly for two months at a cell dosage of 1 × 10⁶ per kg. The primary outcome was a clinical response at 2 months. The levels of cytokines and progerin in the plasma of the patients were analyzed using enz2024-01-01T00:00:00Z2024 Sep2025-05-31T22:19:01.016Z2024-11-09T17:36:09.027ZS-EPMC113680343921894610.1186/s13287-024-03878-y